Clinical Trial Update: A Comparison of Body Fat Distribution in HIV-1 Infected Patients Receiving, Since the Beginning and for at Least Two Years, an Antiretroviral Therapy Based on Efavirenz or Lopinavir/Ritonavir Combined With Tenofovir + Emtricitabine or Lamivudine

View source ↗

Summary

Clinical trial comparing body fat distribution in HIV-1 infected patients on efavirenz- or lopinavir/ritonavir-based ART with tenofovir plus emtricitabine or la…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• EFAVIRENZ (efavirenz)
• Emtricitabine (Emtricitabine)
• Lamivudine (lamivudine)
• Lopinavir/ritonavir (lopinavir/ritonavir)
• TENOFOVIR DISOPROXIL FUMARATE (tenofovir disoproxil fumarate)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: HIV Infection | Status: COMPLETED | Results posted: 2012-10-30